Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or "the Company") (Nasdaq:...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) stock prior to May 16, 2016...
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anacor...
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma PR Newswire NEW YORK, May 20, 2016 NEW YORK, May 20, 2016 /PRNewswire/...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc. -ANAC PR Newswire BALA CYNWYD, Pa., May 19, 2016 BALA CYNWYD, Pa...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) stock prior to May 16, 2016...
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board...
Ryan & Maniskas, LLP Announces Investigation of Anacor Pharmaceuticals, Inc. PR Newswire WAYNE, Pa., May 18, 2016 WAYNE, Pa., May 18, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share -- ANAC PR Newswire NEW...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約